RxDoctor Payments Data

Alon Kahana, MD

Ophthalmic Plastic and Reconstructive Surgery · Livonia, MINPI 1124094651

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $161,258 of the $181,149 with a category attached, or 89.0%. 15 manufacturers reported payments, led by Biotissue Holdings Inc. at 59.4% of the total.

$181,149in general payments, 2019–2025

Across 178 payments — averaging $1017.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$108K
  • Genentech, Inc.$37K
  • Amgen$27K
  • Stryker$8K
  • ANI Pharmaceuticals, Inc.$316
  • AbbVie$142
  • plus $555 from 9 others
$83,302in research payments, 2019–2025

Across 2 payments — averaging $41,651 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$79K
  • F. Hoffmann-la Roche AG$4K

What the payments were for

  • Consulting fees$161,25889%
  • Speaking & faculty fees$13,4607%
  • Travel & lodging$1,8911%
  • Food & beverage$4,5162%
  • Education$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few ophthalmic plastic and reconstructive surgery providers in Michiganto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$247,152
Medicare patients
263
Services billed
1,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj12$557,145
Actemra ActpenTocilizumab14$30,395
Prednisolone Acetate29$1,665
ErythromycinErythromycin Base30$439
Tranexamic Acid34$276
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha12$118
Azithromycin39$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$94$557,14512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few ophthalmic plastic and reconstructive surgery providers in Michiganon file to place this against a meaningful peer group, so we don't.

Other ophthalmic plastic and reconstructive surgery in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →